IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy
- Francesco Pisani1Email author,
- Maria Teresa Petrucci2,
- Diana Giannarelli1,
- Velia Bongarzoni3,
- Marco Montanaro4,
- Valerio De Stefano5,
- Giacinto La Verde6,
- Fabiana Gentilini2,
- Anna Levi2,
- Tommaso Za5,
- Alessandro Moscetti6,
- Luciana Annino3,
- Maria Concetta Petti1 and
- the Multiple Myeloma GIMEMA-Latium Region Working Group, Italy
© Pisani et al; licensee BioMed Central Ltd. 2012
Received: 29 October 2011
Accepted: 1 March 2012
Published: 1 March 2012
Immunoglobulin D multiple myeloma (MM) is rare and has a poorer prognosis than other MM isotypes.
Design and methods
Seventeen patients (pts) diagnosed from 1993 to 2009 with IgD MM were selected from six institutions of Multiple Myeloma Latium-Region GIMEMA Working Group.
Median age was 55 years, 14 patients had bone lesions, eight had renal impairment with estimated glomerular filtration rate (eGFR) < 50 ml/min, one serum calcium ≥ 12 mg/dl, 11 had lambda light chains, five stage III of ISS, six with chromosomal abnormalities. Six pts received conventional chemotherapy (CT): five melphalan + steroids based regimens. Eleven underwent high-doses of chemotherapy with autologous stem cell transplantation (HDT/ASCT), five single and six tandem ASCT: six received bortezomib and/or thalidomide as induction therapy and five VAD. Thalidomide maintenance was used in two pts: one in HDT/ASCT and one in CT group; bortezomib was used in one patient after HDT/ASCT. At a median follow up of 38 (range 19-60) and 50 months (range 17-148) for pts treated with CT and HDT/ASCT, respectively, the overall response rate (ORR) was 83% and 90%. In the group of patients treated with CT, median overall survival (OS) was 34 months (95% CI 15- 54 months), median progression free survival (PFS) was 18 months (95% CI 3-33 months) and median duration of response (DOR) was 7 months (95% CI 5-9 months). Median OS, PFS and DOR were not reached at the time of this analysis in the HDT/ASCT group of patients. Death was observed in 27.3% of pts treated with HDT/ASCT and in 66.7% undergone CT.
Despite the retrospective analysis and the small number of pts our study showed that the use of HDT/ASCT seems to improve also the prognosis of IgD MM patients. Treatment options including new drugs, before and after stem cell transplantation, may further improve the outcomes of these patients.
Immunoglobulin (Ig)D multiple myeloma (IgD MM) is a rare subtype of myeloma, accounts for less than 2% of all myelomas  and is accompanied with aggressive course, resistance to chemotherapy and poor outcome. It is often associated with relatively high frequencies of renal failure, extra osseous disease, hypercalcemia, amyloidosis and Bence-Jones proteinuria [2–5]. The survival of patients with IgD MM has been reported to be shorter than that of patients with other types of M-protein [2, 4, 6]. However, there are reports of long survival in patients with IgD MM treated with alkylating drugs [7–9], interferon-alfa monotherapy  or autologous stem cell transplantation (ASCT) [11–15]. Over the past 10 years, there has been substantial progress in the treatment of MM, prospective randomized trials have shown the superiority of high-doses of chemotherapy with autologous stem cell transplantation (HDT/ASCT) over standard therapy (CT) and new drugs, such as immunomodulatory agents and proteasome inhibitors, have shown effectiveness against disease. These developments may have led to changes in the outcomes of IgD MM.
In this report we present the results of a retrospective analysis of 17 cases with IgD MM treated with CT or HDT/ASCT in six institutions of Multiple myeloma Latium-Region GIMEMA Working Group between 1993 and 2009.
Design and methods
A retrospective analysis was carried out of 17 patients with IgD MM diagnosed from 1993 to 2009 in six institutions from Multiple Myeloma Latium-Region GIMEMA Working Group. Patients who had overt MM based on International Myeloma Working Group (IMWG) diagnostic criteria were selected.
Definition of response
Disease response was assessed using the IMWG criteria [16, 17]. Briefly, a partial response (PR) was defined as a 50% or higher decrease in the serum monoclonal protein (M-protein) levels from baseline and a reduction 90% or greater in 24 hour urine M-protein excretion or less than 200 mg/24 hours; a very good partial respone (VGPR) required a 90% or greater reduction in serum M-protein and urinary M-protein less than 100 mg/24 hours or M-protein detectable by immunofixation but not by electrophoresis. A complete response (CR) was defined as negative serum and urine immunofixation and less than 5% plasma cells on bone marrow examination. Disease that did not satisfy the criteria for PR, VGPR, CR or progressive disease was classified as stable disease (SD). Disease progression required any of the following: 25% or greater increase from lowest response value in serum M-protein (absolute ≥ 0.5 gr/dl) or urine M-protein (absolute ≥ 200 mg/24 hours).
Progression free survival (PFS) was calculated from start of first treatment to disease progression or death from any cause, or the date the patient was last known to be in remission. Overall survival (OS) was calculated from start of first treatment to the date of death or the date the patient was last known to be alive. Duration of response (DOR) was calculated from the time of first response achievement, that is at least PR, to the time of disease progression, with deaths owing to causes other than progression not counted, but censored.
For the analysis of treatment responses, PFS and OS, the patients were divided into two groups: one group was treated with HDT/ASCT, the other group received treatment with conventional-dose chemotherapy.
Data cut-off was April 2011; patient characteristics were summarized using descriptive statistics such as median and range for quantitative variables and frequencies for qualitative.
Progression free survival, overall survival and duration of response were estimated according to the Kaplan-Meier method. We used the Cox proportional hazards regression model to estimate hazard ratios and 95% CIs. Differences between survival curves were tested for statistical significance with the two-sided log-rank test.
Patient characteristics at diagnosis
Number of patients = 17
Median Age at diagnosis yr (range)
55 (37-78) years
≤ 65 y = 13 (76.5%), ≥ 65 y = 4 (23.5%)
ISS stage at diagnosis
ECOG < 2
ECOG > 2
Light chain type
Bone marrow infiltration
Extra osseous disease
Median serum monoclonal protein g/dl
Median Urine monoclonal protein g/24 h
Urine immunofixation positive
Serum β2 microglobulin > 5.5 mg/L
Serum albumin < 3.5 g/dl
eGFR < 50 ml/min
Serum Calcium > 12 mg/dl
Hemoglobin g/dl, median (range)
WBC count 109/L, median (range)
> 7 × 109/L
Platelet count 109/L, median (range)
< 100 × 109/L
Interphase FISH cytogenetic profile results
Number of patients = 17
Six patients were treated with CT, five with Melphalan plus steroids based regimens and one with VAD (Vincristine, Adriamycin and Dexametasone) plus CED (Cyclophosphamide, Etoposide, Dexamethasone); one patient showed a CR, two VGPR, two PR and one SD. Thalidomide was used as maintenance in the patient who obtained CR after CT. The overall response rate (ORR) was 83%; after a median follow up of 38 months (range 19-60) for patient treated with conventional chemotherapy, the median OS was 34 months (95% CI 15- 54 months) and the median PFS was 18 months (95% CI 3-33 months). Median DOR was 7 months (95% CI 5-9 months).
A progression or relapse was observed in 4/11 (36.4%) patients treated with HDT/ASCT and in 4/6 (66.7%) of those undergone CT. The log-rank test for PFS was P = 0.10, the hazard ratio was 0.31 (95% CI 0.07-1.40). One patient who received single ASCT was treated with allogeneic transplantation at relapse. Peripheral neurophaty of grade 1-2 was observed in all patients treated with thalidomide and or bortezomib either in induction or in maintenance therapy. All patients with bone disease received bisphosphonates; patients treated with thalidomide, received aspirin or low molecular-weight heparin as thromboprophylaxis and nobody developed venous thromboembolism.
Seven of 17 patients had died by the time of analysis: four in the group treated with CT and three in the group of HDT/ASCT, 85% of death for disease progression; there were no peritransplant deaths. Comparing OS with log-rank test we obtained P = 0.18, the hazard ratio was 0.37 (95% CI 0.08-1.68). FISH analysis was available only for 6/17 of cases, in these six patients cytogenetic profile had not statistical significance for OS, PFS or DOR
The clinical features of our patients reported in this study underline the worse characteristics of IgD MM. As in other series described in the literature , we also found an advanced stage and a younger age at presentation, with more aggressive clinical course. In addition, the poor survival of the patients may be associated with problems related to delayed diagnosis [13, 19].
Patients with renal failure of unknown cause, bone pain, small serum M-protein bands, or unidentified Ig isotype should be suspected for IgD MM. However, the underlying tumor biology responsible for the differences between IgD MM and other MM isotypes remains to be defined.
IgD MM should be considered a rare subgroup of MM with aggressive features rather than a single parameter of poor prognosis.
Jancelewicz et al.  reported that λ light-chains are found in 90% and almost the totality of patients had Bence-Jones proteinuria. A mean survival of 13.7 months from diagnosis, that was worse than the common myelomas, was observed in this study. Bladé et al  reviews outcomes in 53 patients from 1965 to 1992 and observed λ light-chain disease in 60%, Bence Jones proteinuria in 96%, renal failure in 33% and hypercalcemia in 22%. Shimamoto et al  reviewed 165 cases with IgD MM and on multivariate analysis showed that λ light-chains and white blood cell count > 7 × 109 where adverse prognostic markers. In our series we registered in 11 out of 17 patients (64%) the presence of λ light-chains and Bence-Jones proteinuria in 70%, renal impairment with eGFR < 50 ml/min in 8 cases (47%), extra osseous disease was not seen in our patients at diagnosis. Many studies have shown a poorer prognosis of IgD myeloma than other MM isotypes. Bladé et al.  observed an overall response to therapy of 58% with a median overall survival of 21 months and 5-years survival was 21%. However, these results were obtained before the use high-dose therapy. Wechalekar et al in 11 cases IgD myeloma treated with autologous stem cell transplantation reported 18% CR and 82% PR, compared with a group of 14 patients who received conventional chemotherapy alone in which was observed 0% CR and 43% PR. Maisnar et al  reviewed 26 cases with IgD MM; ten were treated with first-line high-dose chemotherapy using melphalan 200 mg/m2 followed by ASCT and 70% achieved a CR and 100% had at least a PR. The median PFS was18 months for patients who received ASCT and 20 months for those who received conventional chemotherapy. However, the median OS for ASCT group had not been reached, in contrast the median OS for chemotherapy group was only 16 months, which was statistically significant (P = 0.005). More recently Kim et al  retrospectively reviewed 75 patients with IgD myeloma from the Korean Myeloma Registry data base; among 34 patients (45%) treated with ASCT who were in CR or PR, after induction therapy, had a median OS of 30 months (95% CI 17.7-42.3 months) significantly longer than that of patients treated with conventional chemotherapy (16.4 months, P = 0.012).
The small group of patients suffering from IgD multiple myeloma is rare and considered to have a poor prognosis compared to other MM isotypes. Our report, based on analysis of a cohort of 17 patients treated over two decades in six institutions, shows that the use of HDT/ASCT increased OS and PFS by 63% and 69%, respectively, in comparison with those of patients treated with conventional chemotherapy. Thus, the advantage of HDT/ASCT over conventional chemotherapy seems confirmed, although the small number of patients limited the statistical power of the analysis.
New drugs, such bortezomib, thalidomide, lenalidomide used as induction and consolidation in the stem cell transplantation program, may well improve the outcomes of IgDMM.
The clinical features and prognosis of patients with IgDMM differ from those that characterize patients with other immunoglobulin MM subtypes. The underlying tumor biology responsible for these differences remains to be determined. New treatment strategies that aim to induce high-quality responses before ASCT and maintain the response after ASCT may be needed to improve the outcomes of such patients.
estimated Glomerular Filtration Rate
High-dose chemotherapy with autologous stem cell transplantation
Vincristine Adriamycin Dexametasone
Overall Response Rate
Progression Free Survival
duration of response
IgD Multiple Myeloma
International Myeloma Working Group
Very Good Partial Response
Cyclophosphamide Etoposide Dexametasone
International Staging System
Fluorescence in situ Hybridization.
- Bladé J, Kyle RA: Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. ematol Oncol Clin North Am. 1999, 13: 1259-1272. 10.1016/S0889-8588(05)70125-8.View ArticleGoogle Scholar
- Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W: IgD multiple myeloma. Review of 133 cases. Arch Intern Med. 1975, 135: 87-93. 10.1001/archinte.1975.00330010089012.View ArticlePubMedGoogle Scholar
- Fibbe WE, Jansen J: Prognostic factors in IgD myeloma: study of 21 cases. Scand J Haematol. 1984, 33: 471-475.View ArticlePubMedGoogle Scholar
- Bladé J, Lust JA, Kyle RA: Immunoglobulin D multiple myeloma presenting features response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994, 12: 2398-2404.PubMedGoogle Scholar
- Sinclair D: IgD myeloma: clinical, biological and laboratory features. Clin Lab. 2002, 48: 617-622.PubMedGoogle Scholar
- Shimamoto Y, Anamy Y, Yamaguchi M: A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol. 1991, 47: 262-267.View ArticlePubMedGoogle Scholar
- Bemelmans RH, van Toorn DW, van Leeuwen L, Schaar CG: Long-term complete remission in IgD-myeloma. Eur J Haematol. 2006, 76: 339-341. 10.1111/j.1600-0609.2005.00600.x.View ArticlePubMedGoogle Scholar
- Bladé J, Kyle RA: IgD monoclonal gammopathy with long-term follow-up. Br J Haematol. 1994, 88: 395-396. 10.1111/j.1365-2141.1994.tb05037.x.View ArticlePubMedGoogle Scholar
- Kyle RA: IgD multiple myeloma: a cure at 21 years. Am J Hematol. 1988, 29: 41-43. 10.1002/ajh.2830290110.View ArticlePubMedGoogle Scholar
- Hiyoshi M, Hashimoto S, Ota T, Nakao T, Takubo T, Tagawa S, Tatsumi N: Long-term survival in a case of high-risk type IgD myeloma: a possibility of effectiveness of interferon-alpha and erythropoietin. Haematologia (Budapest). 1997, 28: 177-180.Google Scholar
- Wechalekar A, Amato D, Chen C, Keith SA, Reece D: IgD multiple myeloma- a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol. 2005, 84: 115-117. 10.1007/s00277-004-0944-x.View ArticlePubMedGoogle Scholar
- Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MH: The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol. 2010, 85: 502-504. 10.1002/ajh.21740.View ArticlePubMedGoogle Scholar
- Maisnar V, Hájek R, Ščudla V, Gregora E, Büchler T, Tichý M, Kotouček P, Bláha V, Malý J: High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow transplantation. 2008, 41: 51-54. 10.1038/sj.bmt.1705881.View ArticlePubMedGoogle Scholar
- Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispensieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredenson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, Mccarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hart PN: Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma myeloma Leuk. 2010, 10: 458-463. 10.3816/CLML.2010.n.078.PubMed CentralView ArticlePubMedGoogle Scholar
- Morris C, Drake M, Apperly MJ, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Harousseau JL, Morgan G, de Witte T, Niederwieser D, Gahrton G: Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 2010, 95: 2126-2133. 10.3324/haematol.2010.022848.PubMed CentralView ArticlePubMedGoogle Scholar
- Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwing H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadoro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, on behalf of the International Myeloma Working Group: International uniform response criteria for multiple myeloma. Leukemia. 2006, 20: 1467-1473. 10.1038/sj.leu.2404284.View ArticlePubMedGoogle Scholar
- Kyle RA, Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009, 23: 3-9. 10.1038/leu.2008.291.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee G-W, Hang HJ, Kim S-H, Choi CW, Eom HS, Kwak J-Y, Kim HJ, Mun Y-C, Bang S-M, Lee K, Shin HJ, Lee JH: Immunoglobulin D multiple myeloma response to therapy, survival and prognostic factors in 75 patients. Ann Oncol. 2011, 22: 411-416. 10.1093/annonc/mdq393.View ArticlePubMedGoogle Scholar
- Kuliszkiewicz-Janus M, Zimny A, Sokolska V, Saşiadek M, Kuliczkowski K: Immunoglobulin D myeloma-problems with diagnosis and staging (own experience and literature review). Leuk Lymphoma. 2005, 46: 1029-1037. 10.1080/00268970500096442.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.